ASSOCIATION BETWEEN IMMUNE CHECKPOINT INHIBITORS WITH ATHEROSCLEROTIC PLAQUE PROGRESSION AND CARDIOVASCULAR EVENTS IN FEMALE PATIENTS WITH CANCER
Giselle Alexandra Suero‐Abreu(Massachusetts General Hospital), Tomas G. Neilan(Albert Einstein College of Medicine), Carlos A. Gongora(Harvard University), Hajnalka Vágó(Semmelweis University), Hannah Gilman(Massachusetts General Hospital), Júlia Karády(Semmelweis University), Thiago Quinaglia Silva(Massachusetts General Hospital), Kerry L. Reynolds(Massachusetts General Hospital), Markella V. Zanni(Harvard University), Zoltán Varga(University of Szeged), Jor Sam Ho(Massachusetts General Hospital), Borek Foldyna(Cancer Research And Biostatistics), Zsófia D. Drobni(Semmelweis University), Daniel A. Zlotoff(Massachusetts General Hospital), Béla Merkely(Semmelweis University), Jana Taron(University Medical Center Freiburg), Ryan J. Sullivan(Dana-Farber Cancer Institute)
Cited by 1
Related Papers
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.3k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma
|Cell|2018|2k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k